In a report released yesterday, Stephen Macleod from BMO Capital maintained a Buy rating on Jamieson Wellness Inc (JWEL – Research Report), with a price target of C$41.00.
Stephen Macleod’s rating is based on Jamieson Wellness Inc.’s strong performance and promising outlook. The company’s Q4/24 results and 2025 guidance were in line with expectations, demonstrating solid revenue growth and robust consumption trends, particularly in key markets like China and the U.S. The 2025 guidance indicates a return to low double-digit adjusted EBITDA growth, suggesting the company is well-positioned to achieve its long-term revenue target of over $1 billion.
Additionally, Jamieson Wellness Inc. benefits from favorable secular trends and has shown resilience in its operating results, with a notable increase in adjusted EBITDA and margin improvements. The company’s strategic investments, especially in China, are expected to drive further growth, while the risk-reward profile of the stock remains attractive. These factors collectively support Stephen Macleod’s Buy rating for the stock.
According to TipRanks, Macleod is a 5-star analyst with an average return of 11.5% and a 58.20% success rate. Macleod covers the Consumer Cyclical sector, focusing on stocks such as Aritzia, Gildan Activewear, and CCL Industries.
In another report released today, RBC Capital also maintained a Buy rating on the stock with a C$40.00 price target.